Botulinum toxin for foot dystonia in patients with Parkinsonâ€™s disease having deep brain stimulation: A case series and a pilot study

Gupta, Anupam Datta; Visvanathan, Renuka

doi:10.2340/16501977-2094

Cited by 27 publications

(23 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Além dos testes Timed Up and Go (TUG) que é um teste básico de mobilidade funcional, onde o paciente se levanta da cadeira, caminha três metros e volta a sentar-se na cadeira, o teste de caminhada de 6 minutos, que mede a capacidade de exercício funcional 21 , e a velocidade e cadência de marcha foram avaliadas pela Escala Goal Attainment Scaling (GAS) 16 .…”

Section: Os Resultados Primários Foram Medidos Através Daunclassified

“…A extração dos dados para o processo de elegibilidade dos estudos foi realizada utilizando-se uma ficha própria para revisão sistemática elaborada por dois pesquisadores em 16 . A escala SCS-PD é uma avaliação subjetiva, com sete questões que avaliam a gravidade e a frequência de salivação, assim como o comprometimento social e funcional.…”

Section: Análise Dos Dadosunclassified

See 1 more Smart Citation

Impacto do uso da Toxina Botulínica em pacientes com Doença de Parkinson: uma revisão Sistemática

Souza¹,

Gonçalves²,

Mituuti³

et al. 2021

Rev Neurocienc

View full text Add to dashboard Cite

Introdução. A Toxina Botulínica (TxB) vem sendo amplamente utilizada para tratar sintomas da doença de Parkinson (DP) e sua eficácia e segurança vem sendo confirmada em diversos estudos. Objetivo. Verificar o impacto do uso da toxina botulínica em pacientes com DP. Método. A busca por artigos científicos foi conduzida por dois pesquisadores independentes nas bases de dados MEDLINE (Pubmed), LILACS, SciELO, SCOPUS, WEB OF SCIENCE e BIREME, sem restrição de idioma e localização, durante o período de 2015 a 2020. Para complementar e evitar viés de risco foi realizada uma busca por literatura cinza no Google Scholar. A revisão sistemática foi conduzida conforme as recomendações do Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Foram inclusos na pesquisa estudos que obtiveram pontuação ≥ a 6 pontos segundo o protocolo para pontuação qualitativa proposto por Pithon et al. Resultados. Foram recuperados 97 artigos com potencial de inclusão, sendo que 4 responderam à pergunta norteadora, que consistiu em verificar o impacto do uso da TxB em pacientes com DP. Os artigos selecionados relataram o uso da TxB para tratar a sialorreia, tremor e distonia dos pés. O uso da TxB mostrou-se eficaz a longo prazo para tratar a sialorreia, distonia dos pés e tremor de membro. Conclusão. As análises evidenciaram que a TxB possui um impacto positivo aos pacientes com DP, sendo uma grande aliada na melhora da qualidade de vida desses pacientes, tendo poucos efeitos colaterais, sendo em sua maioria leves.

show abstract

Section: Os Resultados Primários Foram Medidos Através Daunclassified

Section: Análise Dos Dadosunclassified

Impacto do uso da Toxina Botulínica em pacientes com Doença de Parkinson: uma revisão Sistemática

Souza¹,

Gonçalves²,

Mituuti³

et al. 2021

Rev Neurocienc

View full text Add to dashboard Cite

show abstract

“…This negatively affects the quality of life, producing pain and making it difficult to wear footwear [24]. Although botulinum toxin is routinely used as a therapeutic, more studies are needed to support the notion that this is an effective treatment [25,26].…”

Section: Ivyspringmentioning

confidence: 99%

Impact of Footwear and Foot Deformities in patients with Parkinson's disease: A Case-Series Study

Novo-Trillo¹,

López‐López²,

Labra³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) is a common and complex neurological problem. Gait abnormalities are frequent in PD patients, and this increases the risk of falls. However, little is known about foot deformities and footwear in this vulnerable population. Here we investigate whether patients with PD use an appropriate shoe size and know if they have foot deformities or alterations. Methodology: A study of a series of observational descriptive cases in a convenience sample (n = 53 patients) diagnosed with Parkinson's disease. One trained investigator evaluated foot and ankle health. The footwear and foot measurements were obtained using a Brannock device. Results: The podiatric examination and footwear examination detected a high presence of podiatric pathologies and inappropriate footwear. This has a negative impact on the quality of life of these patients. Conclusions: This research detected an elevated number of people with foot deformities or alterations. Moreover, a high proportion of participants with PD wear inadequate footwear (in length, width, or both).

show abstract

“…46 Three other studies with < 10 patients each reported variable responses, although some studies included patients with fixed dystonia and contractures that likely limited the potential benefits. [47][48][49] A recent expert panel review of the available literature on the treatment of limb dystonia (not just PD) with BoNT resulted in a level B recommendation for abobotulinum and onabotulinum based on one class I 50 and one class II for abobotulinum, 51 and three class II studies for onabotulinum. 11,[52][53][54] The majority of these were limited to writer's cramp dystonia, but at least one included a mixed patient population inclusive of some poststroke dystonia.…”

Section: Limb Dystoniamentioning

confidence: 99%

Botulinum Toxin Therapy for Parkinson's Disease

Shukla

Malaty

2017

Semin Neurol

View full text Add to dashboard Cite

Botulinum toxin (BoNT) therapy is frequently employed in the treatment of Parkinson's disease (PD) symptoms. It can effectively ameliorate the symptoms of cervical dystonia, blepharospasm, sialorrhea, and hyperactive bladder. It is increasingly being used for additional PD-related indications including limb dystonia, oromandibular dystonia, tremors, constipation, dysphagia, gastroparesis, and sweating dysfunction. Botulinum toxin treatment has mostly local side effects and does not interfere with dopaminergic therapies prescribed for PD. With the exception of dystonia and sialorrhea, most evidence for BoNT efficacy is derived from studies conducted in nonparkinsonian populations. Thus, the data to inform typical response pattern and side-effect profile in PD are still evolving. Nevertheless, BoNT is widely used and is an important tool in the PD-treatment arsenal. In this review, the authors discuss the current literature on the use of BoNT in various PD-related motor and nonmotor disorders.

show abstract

Botulinum toxin for foot dystonia in patients with Parkinsonâ€™s disease having deep brain stimulation: A case series and a pilot study

Abstract: Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson's disease with deep brain stimulation.

Cited by 27 publications

References 8 publications

Impacto do uso da Toxina Botulínica em pacientes com Doença de Parkinson: uma revisão Sistemática

Impacto do uso da Toxina Botulínica em pacientes com Doença de Parkinson: uma revisão Sistemática

Impact of Footwear and Foot Deformities in patients with Parkinson's disease: A Case-Series Study

Botulinum Toxin Therapy for Parkinson's Disease

Contact Info

Product

Resources

About